Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology
Journal of Cellular Physiology · 2026-03 · 241 (3)
DOI: 10.1002/jcp.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, online erschienen am 26.03.2026. Verfasst von Durgesh Meena und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Immunity, Innate, Mitochondrial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Ministry of Electronics and Information Technology, Government of India, Council of Scientific & Industrial Research, Department of Biotechnology (DBT)-JRF Fellowship.
Abstract (Originalsprache)
Gliomas are primary brain tumors that develop from glial cells within the central nervous system and are among the deadliest human cancers. Glioblastoma (GBM) is the most malignant form of glioma. NLRX1 is an innate immune pattern recognition receptor that exhibits tumor‐suppressive or tumor‐promoting effects that may be cancer type‐ and context‐dependent, aided by differences in the microenvironment. Here, we report that NLRX1 is differentially expressed in microglia, astrocytes, GBM cell lines, and glioma patient tissues. siRNA‐mediated silencing of NLRX1 induces metabolic stress in GBM cells, as observed by an increased number of tunneling nanotubes (TNTs) formation between GBM cells and decreased expression of autophagy markers. Moreover, silencing of NLRX1 decreases the ability of the GBM cell lines, LN‐229 and LN‐18, to proliferate and migrate. si‐NLRX1 GBM cells exhibit attenuated ability to generate 3D spheroids. In summary, our findings indicate that NLRX1 positively regulates GBM pathophysiology by supporting GBM cell metabolism, proliferation, migration, and anchorage‐independent growth. We believe our understanding of NLRX1 in GBM pathophysiology paves the way for potential development of GBM‐targeting therapeutics that may delay disease progression and/or improve survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India.
- Department of Computer Science and Engineering, Indian Institute of Technology Jodhpur, Jodhpur, Rajasthan, India.
- Department of Neurosurgery, All India Institute of Medical Sciences Jodhpur, Jodhpur, Rajasthan, India.
ORCID-Profile: Sushmita Jha
Förderung
- Ministry of Electronics and Information Technology, Government of India
- Council of Scientific & Industrial Research
- Department of Biotechnology (DBT)-JRF Fellowship
- Department of Science and Technology (DST)/INSPIRE Fellowship
Zitieren
APA
Meena, D., Shivakumar, D., Rajkhowa, S., Solanki, P., Chhipa, S., Bhattacharya, N., Revanth, M. S., Kumar, D., Janu, V., Garg, M., Gosal, J. S., & Jha, S. (2026). Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology. Journal of Cellular Physiology, 241(3). https://doi.org/10.1002/jcp.70163
Vancouver
Meena D, Shivakumar D, Rajkhowa S, Solanki P, Chhipa S, Bhattacharya N, et al. Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology. Journal of Cellular Physiology. 2026;241(3). doi:10.1002/jcp.70163
BibTeX
@article{Meena2026,
author = {Meena, Durgesh and Shivakumar, Divya and Rajkhowa, Sushmita and Solanki, Priya and Chhipa, Shalini and Bhattacharya, Neermita and Revanth, M S and Kumar, Deepak and Janu, Vikas and Garg, Mayank and Gosal, Jaskaran Singh and Jha, Sushmita},
title = {Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology},
journal = {Journal of Cellular Physiology},
year = {2026},
volume = {241},
number = {3},
doi = {10.1002/jcp.70163}
}
EUVIMED